T
Timothy Hardy
Researcher at Newcastle University
Publications - 10
Citations - 3359
Timothy Hardy is an academic researcher from Newcastle University. The author has contributed to research in topics: Fatty liver & Fibrosis. The author has an hindex of 6, co-authored 10 publications receiving 1929 citations. Previous affiliations of Timothy Hardy include Newcastle upon Tyne Hospitals NHS Foundation Trust & Freeman Hospital.
Papers
More filters
Journal ArticleDOI
Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention
Zobair M. Younossi,Quentin M. Anstee,Milena Marietti,Timothy Hardy,Timothy Hardy,Linda Henry,Mohammed Eslam,Jacob George,Elisabetta Bugianesi +8 more
TL;DR: The large number of patients with NAFLD with potential for progressive liver disease creates challenges for screening, as the diagnosis of NASH necessitates invasive liver biopsy.
Journal ArticleDOI
Systematic review assessing the effectiveness of dietary intervention on gut microbiota in adults with type 2 diabetes.
David Houghton,Timothy Hardy,Christopher J. Stewart,Linda Errington,Christopher P. Day,Michael I. Trenell,Leah Avery +6 more
TL;DR: Dietary intervention was found to modulate the gut microbiota and improve glucose control in individuals with type 2 diabetes, and highlights the need for further well-conducted interventional studies to inform the clinical use of dietary interventions targeting the Gut microbiota.
Journal ArticleDOI
A Proof-of-Concept for Epigenetic Therapy of Tissue Fibrosis: Inhibition of Liver Fibrosis Progression by 3-Deazaneplanocin A
Müjdat Zeybel,Saimir Luli,Laura Sabater,Timothy Hardy,Fiona Oakley,Jack Leslie,Agata Page,Eva Moran Salvador,Victoria Sharkey,Hidekazu Tsukamoto,David C. K. Chu,Uma S. Singh,Mirco Ponzoni,Patrizia Perri,Daniela Di Paolo,Edgar J. Mendivil,Jelena Mann,Derek A. Mann +17 more
TL;DR: The in vivo modulation of HSC histone methylation is sufficient to halt progression of fibrosis in the context of continuous liver damage, and the novel HSC-targeting vehicle, which avoids the unwanted effects of epigenetic drugs on parenchymal liver cells, represents an important proof-of-concept for epigenetic treatment of liver fibrosis.
Journal ArticleDOI
The European NAFLD Registry: A real-world longitudinal cohort study of nonalcoholic fatty liver disease
Timothy Hardy,Kristy Wonders,Ramy Younes,Guruprasad P. Aithal,Rocío Aller,Michael Allison,Pierre Bedossa,Fay Betsou,Jérôme Boursier,M. Julia Brosnan,Alastair D. Burt,Jeremy Cobbold,Helena Cortez-Pinto,Christopher P. Day,Jean-François Dufour,Mattias Ekstedt,Sven Francque,Seamus Conor Harrison,Luca Miele,Patrik Nasr,George V. Papatheodoridis,Salvatore Petta,Dina Tiniakos,Richard Torstenson,Luca Valenti,Adriaan G. Holleboom,Hannele Yki-Järvinen,Andreas Geier,Manuel Romero-Gómez,Vlad Ratziu,Elisabetta Bugianesi,Jörn M. Schattenberg,Quentin M. Anstee +32 more
TL;DR: The infrastructure, data management and monitoring plans, and the standard operating procedures implemented to ensure the timely and systematic collection of high-quality data and samples are described.
Journal ArticleDOI
The degree of hepatic steatosis associates with impaired cardiac and autonomic function
David Houghton,Paweł Zalewski,Kate Hallsworth,Sophie Cassidy,Christian Thoma,Leah Avery,Joanna Słomko,Timothy Hardy,Alastair D. Burt,Dina Tiniakos,Kieren G. Hollingsworth,Roy Taylor,Christopher P. Day,Christopher P. Day,Steven Masson,Steven Masson,Stuart McPherson,Stuart McPherson,Quentin M. Anstee,Quentin M. Anstee,Julia L. Newton,Julia L. Newton,Michael I. Trenell +22 more
TL;DR: Cardiac and autonomic impairments appear to be dependent on level of liver fat, metabolic dysfunction, inflammation and fibrosis staging, and to a lesser extent alcohol intake.